Nonalcoholic Steatohepatitis: Role of Leptin in Pathogenesis and Benefits of Metformin in Treatment [2] (multiple letters)

American Journal of Gastroenterology

Volumn 98, Issue 10, 2003, Pages 2330-

  Kadayifçi, Abdurrahman ^a,b   Hookman, Perry ^c   Barkin, Jamie S ^c,d  

^a Fevzi Cakmak Bulv   (Turkey)

^b GAZIANTEP UNIVERSITY   (Turkey)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LACTIC ACID; LEPTIN; METFORMIN;

CLINICAL TRIAL; DIET THERAPY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FATTY LIVER; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; LACTATE BLOOD LEVEL; LEPTIN BLOOD LEVEL; LETTER; LIPID DIET; LIPID METABOLISM; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOGENESIS; PRIORITY JOURNAL;

EID: 0142245751     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9270(03)00769-x     Document Type: Letter

References (4)

1. P. Hookman J.S. Barkin Current biochemical studies of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) suggest a new therapeutic approach Am J Gastroenterol 98 2003 495 499
2. H.Z. Lin S.Q. Yang C. Chuckaree Metformin reverses fatty liver disease in obese, leptin deficient mice Nat Med 6 2000 998 1003
3. A. Uygun A. Kadayifci Z. Yesilova Serum leptin levels in patients with nonalcoholic steatohepatitis Am J Gastroenterol 95 2000 3584 3589
4. G. Marchesini M. Brizi G. Bianchi Metformin in non-alcoholic steatohepatitis Lancet 358 2001 893 894